676494-70-5

Basic information

• Product Name: 3-Pyridinecarboxamide, 6-(4-formylphenoxy)-
• CAS NO: 676494-70-5
• Molecular Formula: C13H10N2O3
• Molecular Weight: 242.234
• Mol File: 676494-70-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-Pyridinecarboxamide, 6-(4-formylphenoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarboxamide, 6-(4-formylphenoxy)-(676494-70-5)
• EPA Substance Registry System: 3-Pyridinecarboxamide, 6-(4-formylphenoxy)-(676494-70-5)

Safety Data

• Hazardous Substances Data: 676494-70-5(Hazardous Substances Data)

Upstream product

• 3939-12-6 6-fluoro-3-pyridinecarbonitrile 
• 123-08-0 4-hydroxy-benzaldehyde 
• 676501-68-1 6-(4-formylphenoxy)-3-pyridinecarbonitrile 
• 6271-78-9 6-chloro-3-pyridinecarboxamide 

Downstream Products

• 1346133-15-0 6-[4-[ (3,3-dimethyl-2-phenyl-azetidin-1-yl)methyl]phenoxy]pyridine-3-carboxamide 
• 1346133-17-2 6-[4-[[(2S)-3,3-dimethyl-2-phenyl-azetidin-1-yl]methyl]phenoxy]pyridine-3-carboxamide 
• 1346133-16-1 6-[4-[[(2R)-3,3-dimethyl-2-phenyl-azetidin-1-yl]methyl]phenoxy]pyridine-3-carboxamide 
• 1346133-14-9 6-[4-[[ (3-hydroxy-2,2-dimethyl-1-phenyl-propyl)amino]methyl]phenoxy]pyridine-3-carboxamide 
• 1346133-06-9 6-[4-[ [2-(3-pyridyl)pyrrolidin-1-yl]methyl]phenoxy]pyridine-3-carboxamide 
• 1423875-10-8 C₃₃H₃₁N₃O₄S 
• 1423875-08-4 C₂₄H₂₅N₃O₃S 
• 1423875-07-3 C₂₄H₂₅N₃O₄ 
• 1423875-12-0 C₃₂H₂₈FN₃O₃S 
• 1423875-11-9 C₃₂H₂₈N₄O₅S 
• 1000995-43-6 C₂₂H₂₁N₃O₂ 
• 676495-63-9 6-{4-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-phenoxy}-nicotinamide 

Relevant articles and documents

Potent and selective tariquidar bioisosters as potential PET radiotracers for imaging P-gp

Compounds 8a-d have been designed as bioisosters of tariquidar for imaging P-gp expression and density by PET. The results displayed that compounds 8b and 8d could be considered potential P-gp/BCRP ligands suitable as 11C and 18F radiotracers, respectively.

DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST

A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3', E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.